A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

Trial Profile

A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Cefepime/tazobactam (Primary)
  • Indications Renal impairment
  • Focus Pharmacokinetics
  • Sponsors Wockhardt
  • Most Recent Events

    • 25 Aug 2016 Status changed to completed.
    • 25 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top